Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Multicenter Phase 1b Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive HER2-Negative Breast Cancer

NCT04288089 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT04288089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04288089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Multicenter Phase 1b Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive HER2-Negative Breast Cancer
Lead sponsor
Eisai Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 1, 2020
Completion date
March 31, 2027
Enrollment
31 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms, genes, erbb-2, receptors, estrogen